[1]
|
O. J. Finn, “Cancer Vaccines: Between the Idea and the Reality,” Nature Reviews Immunology, Vol. 3, No. 8, 2003, pp. 630-641. doi:10.1038/nri1150
|
[2]
|
S. B. Ho, G. A. Niehans, C. Lyftogt, P. S. Yan, D. L. Cherwitz, et al., “Heterogeneity of Mucin Gene Expression in Normal and Neoplastic Tissues,” Cancer Research, Vol. 53, No. 3, 1993, pp. 641-651.
|
[3]
|
J. Taylor-Papadimitirou, J. Burchell, D. W. Miles and M. Dalziel, “MUC1 and Cancer,” Biochimica et Biophysica Acta, Vol. 1455, No. 2-3, 1999, pp. 301-313.
doi:10.1016/S0925-4439(99)00055-1
|
[4]
|
M. A. McGuckin, M. D. Walsh, B. G. Hohn, B. G. Ward and R. G. Wright, “Prognostic Significance of MUC1 Epithelial Mucin Expression in Breast Cancer,” Human Pathology, Vol. 26, No. 4, 1995, pp. 432-439.
doi:10.1016/0046-8177(95)90146-9
|
[5]
|
A. M. Vlad, J. C. Kettel, N. M. Alajez, C. A. Carlos and O. J. Finn, “MUC1 Immunobiology: From Discovery to Clinical Applications,” Advances in Immunology, Vol. 82, 2004, pp. 249-293. doi:10.1016/S0065-2776(04)82006-6
|
[6]
|
E. Yang, X. F. Hu and P. X. Xing, “Advances of MUC1 as a Target for Breast Cancer Therapy,” Histology and Histopathology, Vol. 22, No. 8, 2007, pp. 905-922.
|
[7]
|
S. M. Newton, C. O. Jacob and B. A. Stocker, “Immune Response to Cholera Toxin Epitope Inserted in Salmonella Flagellin,” Science, Vol. 244, No. 4900, 1989, pp. 70-72. doi:10.1126/science.2468182
|
[8]
|
R. Levi and R. Arnon, “Synthetic Recombinant Influenza Vaccine Induces Efficient Long-Term Immunity and Cross-Strain Protection,” Vaccine, Vol. 4, No. 1, 1996, pp. 85-92. doi:10.1016/0264-410X(95)00088-I
|
[9]
|
T. Ben-Yedidia, R. Tarrab-Hazdai, D. Schechtman and R. Arnon, “Instranasal Administration of Synthetic Recombinant Peptide-Based Vaccine Protects Mice from Infection by Schistosoma Mansoni,” Infection and Immunity, Vol. 67, No. 9, 1999, pp. 4360-4366.
|
[10]
|
T. Ben-Yedidia, H. Marcus, Y. Reisner and R. Arnon, “Intranasal Administration of Peptide Vaccine Protects Human/Mouse Radiation Chimera from Influenza Infection,” International Immunology, Vol. 11, No. 7, 1999, pp. 1043-1051. doi:10.1093/intimm/11.7.1043
|
[11]
|
A. N. Honko, N. Siranganathan, C. J. Lees, S. B. Mizal, “Flagellin Is an Effective Adjuvant for Immunization against Lethal Respiratory Challenge with Yersinia Pestis,” Infection and Immunity, Vol. 74, No. 2, 2006, pp. 1113-1120. doi:10.1128/IAI.74.2.1113-1120.2006
|
[12]
|
B. L. Whittle, E. Lee, R. C. Weir and N. K. Verma, “Immune Response to a Murray Valley Encephalitis Virus Epitope Expressed in the Flagellin of an Attenuated Strain of Salmonella,” Journal of Medical Microbiology, Vol. 46, No. 2, 1997, pp. 129-138.
doi:10.1099/00222615-46-2-129
|
[13]
|
N. K. Verma, H. K. Ziegler, B. A. Stocker and G. K. Schoolnick, “Induction of a Cellular Immune Response to a Defined T-Cell Epitope as an Insert in the Flagellin of a Live Vaccine Strain in Salmonella,” Vaccine, Vol. 13, No. 3, 1995, pp. 235-244.
doi:10.1016/0264-410X(95)93308-V
|
[14]
|
C. Cuadros, F. J. Lopez-Hernandez, A. L. Dominguez, M. McClelland and J. Lustgartent, “Flagellin Fusion Proteins as Adjuvants or Vaccines Induce Specific Immune Response,” Infection and Immunity, Vol. 72, No. 5, 2004, pp. 2810-2816. doi:10.1128/IAI.72.5.2810-2816.2004
|
[15]
|
D. Van Duin, R. Medzhitov and A. C. Shaw, “Triggering TLR Signalling in Vaccination,” Trends in Immunology, Vol. 27, No. 1, 2006, pp. 49-55.
doi:10.1016/j.it.2005.11.005
|
[16]
|
T. Ben-Yedidia and R. Arnon, “Effect of Pre-Existing Carrier Immunity on the Efficacy of Synthetic Influenza Vaccine,” Immunology Letters, Vol. 64, No. 1, 1998, pp. 9-15. doi:10.1016/S0165-2478(98)00073-X
|
[17]
|
G. H. Rammensee, J. Bachmann, N. N. Emmerich, O. A. Bachor and S. Stevanovic, “SYFPEITHI: Database for MHC Ligands and Peptide Motifs,” Immunogenetics, Vol. 50, No. 3-4, 1999, pp. 213-219. www.syfpeithi.de
doi:10.1007/s002510050595
|
[18]
|
E. H. Moase, W. Qi, T. Ishida, Z. Gabos, B. M. Longenecker, et al., “Anti-MUC-1 Immunoliposomal Doxorubicin in the Treatment of Murine Models of Metastatic Breast Cancer,” Biochimica et Biophysica Acta, Vol. 1510, No. 1-2, 2001, pp. 43-55.
doi:10.1016/S0005-2736(00)00334-5
|
[19]
|
G. J. Rowse, R. M. Tempero, M. L. VanLith, M. A. Hollingworth and S. J. Gendler, “Tolerance and Immunity to MUC1 in a Human MUC1 Transgenic Murine Model,” Cancer Research, Vol. 58, No. 2, 1998, pp. 314-321.
|
[20]
|
S. J. McSorley, B. D. Ehst, Y. Yu and A. T. Gewirtz, “Bacterial Flagellin is an Effective Adjuvant for CD4+ T Cells in Vivo,” The Journal of Immunology, Vol. 169, No. 7, 2002, pp. 3914-3919.
|
[21]
|
L. Sfrondini, A. Rossini, D. Besusso, A. Merlo, E. Tagliabue, et al., “Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer,” The Journal of Immunology, Vol. 176, No. 11, 2006, pp. 6624-6630.
|
[22]
|
L. Strindelius, M. Filler and I. Sjoholm, “Mucosal Immunization with Purified Flagellin from Salmonella Induces Systemic and Mucosal Immune Response in CH3/HEJ Mice,” Vaccine, Vol. 22, No. 27-28, 2004, pp. 3797-3808. doi:10.1016/j.vaccine.2003.12.035
|
[23]
|
S. Agrawal, A. Agrawal, B. Doughty, A. Gerwitz, J. Blenis, et al., “Cutting Edge: Different Toll-Like Receptor Agonists Instruct Dendritic Cells to Induce Distinct Th Responses via Differential Modulation of Extracellular Signal-Regulated Kinase-Mitogen-Activated Protein Kinase and c-Fos,” The Journal of Immunology, Vol. 171, No. 10, 2003, pp. 4984-4989.
|
[24]
|
A. Didierlaurent, I. Ferrero, L. A. Otten, B. Dubois, M. Reinhardt, et al., “Flagellin Promotes Myeloid Differentiation Factor 88-Dependent Development of Th2-Type Response,” The Journal of Immunology, Vol. 172, No. 11, 2004, pp. 6922-6930.
|
[25]
|
R. M. Salazar-Gonzalez and S. J. McSorley, “Salmonella Flagellin a Microbial Target of the Innate and Adaptive Immune System,” Immunology Letters, Vol. 101, No. 2, 2005, pp. 117-122. doi:10.1016/j.imlet.2005.05.004
|
[26]
|
S. Ho Jeon, T. Ben-Yedidia and R. Arnon, “Intranasal Immunization with Synthetic Recombinant Vaccine Containing Multiple Epitopes of Influenza Virus,” Vaccine, Vol. 20, No. 21-22, 2002, pp. 2772-2780.
doi:10.1016/S0264-410X(02)00187-1
|
[27]
|
P. Zheng, S. Sarma, Y. Guo and Y. Liu, “Two Mechanisms for Tumor Evasion of Preexisting Cytotoxic T-Cell Responses: Lessons from Recurrent Tumors,” Cancer Research, Vol. 59, No. 14, 1999, pp. 3461-3467.
|
[28]
|
N. M. Alajez, J. Schmielau, M. D. Alter, M. Casio and O. J. Finn, “Therapeutic Potential of a Tumor-Specific MHC-Unrestricted T-Cell Receptor Expressed on Effector Cells of the Innate and the Adaptive Immune System through Bone Marrow Transduction and Immune Reconstitution,” Blood, Vol. 105, No. 12, 2005, pp. 4583-4589.
doi:10.1182/blood-2004-10-3848
|
[29]
|
R. K. Ramanathan, K. M. Lee, J. McKolanis, E. Hitbold, W. Schraut, et al., “Phase I Study of a MUC1 Vaccine Composed of Different Doses of MUC1 Peptide with SBAS2 Adjuvant in Resected and Locally Advanced Pancreatic Cancer,” Cancer Immunology, Immunotherapy, Vol. 54, No. 3, 2004, pp. 254-264.
doi:10.1007/s00262-004-0581-1
|
[30]
|
B. Acres, “Cancer Immunotherapy: Plase II Clinical Studies with TG4010 (MVA-MUC1-IL2),” Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology, Vol. 12, Suppl. 1, 2007, pp. S71-S75.
|
[31]
|
V. Apostolopoulos, G. A. Pietersz, A. Tsibanis, A. Tsikkinis, H. Drakaki, et al., “Pilot Phase III Immunotherapy Study in Early Stage Breast Cancer Patients Using Oxidized Mannan-MUC1,” Breast Cancer Research, Vol. 8, No. 3, 2006, pp. 27-32.
doi:10.1186/bcr1505
|
[32]
|
R. Sangha and S. North, “L-BLP25: A MUC1 Targeted Peptide Vaccine Therapy in Prostate Cancer,” Expert Opinion on Biological Therapy, Vol. 7, No. 11, 2007, pp. 1723-1730. doi:10.1517/14712598.7.11.1723
|
[33]
|
J. Wierecky, M. R. Müller, S. Wirths, E. Halder-Oehler, D. D?rfel, et al., “Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastasic Renal Cancer Patients,” Cancer Research, Vol. 66, No. 11, 2006, pp. 5910-5918.
doi:10.1158/0008-5472.CAN-05-3905
|
[34]
|
K. Yamamoto, T. Ueno, T. Kawaoka, S. Hazama, M. Fukui, et al. “MUC1 Peptide Vaccination in Patients with Advanced Pancreas or Biliary Tract Cancer,” Anticancer Research, Vol. 25, No. 5, 2005, pp. 3575-3579.
|
[35]
|
D. T. O’Hagan, M. L. MacKichan and M. Singh, “Recent Developments in Adjuvants for Vaccines against Infectious Diseases,” Biomolecular Engineering, Vol. 18, No. 3, 2001, pp. 69-85.
doi:10.1016/S1389-0344(01)00101-0
|
[36]
|
N. Yajima, R. Yamanaka, T. Mine, N. Tsuchiya, J. Homma, et al., “Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma,” Clinical Cancer Research, Vol. 11, No. 16, 2005, pp. 5900-5911.
doi:10.1158/1078-0432.CCR-05-0559
|
[37]
|
C. Pasare and R. Medzhitov, “Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells,” Science, Vol. 299, No. 5609, 2005, pp. 1033-1036. doi:10.1126/science.1078231
|